Leukocyte adherence mediated by intercellular adhesion molecule-1 (ICAM-1)
binding to leukocyte function-associated antigen (LFA-1) is required for pr
oper inflammatory and immune function. Inhibition of ICAM-1\LFA-1 binding u
sing monoclonal antibodies (mAb) has been shown to be efficacious at inhibi
ting lymphoma metastasis as well as leukocyte emigration into tissue in a n
umber of inflammatory diseases such as ischemia-reperfusion injury, septic
shock and rheumatoid arthritis. In this report, we describe the development
and characterization of a small peptide antagonist of ICAM-1-dependent cel
l aggregation. By using repeated selection of a cyclic nonapeptide phage di
splay library on purified ICAM-1, we identified phage that were competitive
ly eluted with anti-ICAM-1 mAb. The peptide sequences were determined by nu
cleotide sequencing, and the peptide sequence (C*LLRMRSIC*) (IP01) that occ
urred most frequently was chosen for further study. Phage expressing this p
eptide sequence specifically bound ICAM-1 over a range of 5x10(6) to 1x10(8
) phage/muL. A cyclic IP01 peptide, linear IP01 peptide, a cyclic nonapepti
de with a scrambled IP01 sequence, and a random, cyclic nonapeptide were sy
nthesized. The cyclic and linear IP01 peptides were able to inhibit ICAM-1-
mediated cell aggregation at a concentration of 1 mm, whereas the random an
d scrambled peptide sequences did not alter aggregation. Cyclic IP01 had a
half-maximal inhibitory concentration of approximate to 970 muM. Cyclic IP0
1 did not inhibit cellular aggregation that was dependent on ICAM-2 or ICAM
-3. Alanine substitutions in the cyclic IP01 identified at least four amino
acids necessary for inhibition of ICAM-1 dependent cell aggregation; leuci
ne 2, leucine 3, methionine 5, and arginine 6. Finally, we showed that cycl
ic IP01 can inhibit firm adhesion of neutrophils to endothelium, a critical
event in inflammatory diseases, in an assay that recapitulates physiologic
flow conditions. Homology of IP01 with the primary amino acid sequences of
the alpha or beta subunit of LFA-1 was not identified. Thus, we identified
a unique molecule that inhibits ICAM-1 dependent cell adhesion, but is not
related to the primary sequence of the ICAM-1 ligand LFA-1. Due to the sma
ll size and ability to block cell-cell adhesion, IP01 may serve as a useful
tool for study of ICAM-1 and LFA-1 biology as well as for the development
of small molecule therapeutics.